We offer adequate clinical diagnosis with the support of a multidisciplinary team and a centre for clinical trials. Research in the Laboratory of Neuroscience mainly focuses on genetics of ALS, ALS disease mechanisms using in vitro cell models, iPSCs as a bioassay of clinical relevance, and biomarker identification. We have made a big effort to develop eye tracking and BCI technologies for the definition of neuropsychological changes in people with ALS. The Milan ALS Centre has been audited by FDA in 1997 for a clinical trial.
Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound ‘AMX0035’ for the treatment of ALS.
Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.